|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||7.32 - 7.50|
|52 Week Range||5.45 - 7.55|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||8.40|
MedinCell receives a grant from The Bill & Melinda Gates Foundation for a product aimed at preventing HIV infection. Pre-exposure prophylaxis (PrEP) strategy has proven efficacy in preventing HIV infection via daily oral administration of antiretroviral drugs. A combination of an investigational PrEP single-agent with MedinCell's long-acting injectable technology could guarantee several months of prevention after a single subcutaneous injection.
MedinCell (MEDCL.PA) partners with Cornerstone Animal Health to develop a range of best-in-class long-acting injectable veterinary products using MedinCell’s BEPO® proprietary technology. Cornerstone Animal Health is a US-based Animal Health commercialization group formed by seasoned industry veterans, most of them former executives of iconic companies such as Pfizer Animal Health (Zoetis), Merck Animal Health or Merial. The Cornerstone team has an extensive network, deep experience from regulatory development to successful commercialization of innovative products in Animal Health as well as channel management to get products launched.
A second long-acting injectable antipsychotic using MedinCell's technology has received FDA IND* clearance to initiate clinical activities. “We have achieved our goal of having at least one clinical trial authorization per year”, stated Christophe Douat, CEO of MedinCell.
If you want to know who really controls MedinCell S.A. (EPA:MEDCL), then you'll have to look at the makeup of its share registry. Institutions will often hold stock in bigger Read More...